# A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

> **NCT04562870** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Karyopharm Therapeutics Inc** · enrollment: 112 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Selinexor
- **OTHER:** Physician's Choice Treatment

## Key facts

- **NCT ID:** NCT04562870
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-17
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562870, "A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04562870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*